Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Crews

Showing results (121-130 of 173) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2018
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline UpdateNaren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2018
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline UpdateSharon H Giordano, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumorsWayne L Furman, Fariba Navid, Najat C Daw, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 13, 2014
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogeneticsJames M Hoffman, Cyrine E Haidar, Mark R Wilkinson, et al.
Blood|May 16, 2014
6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group studySmita Bhatia, Wendy Landier, Lindsey Hageman, et al.
Pharmacogenomics|April 1, 2011
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypesJatinder K Lamba, Kristine R Crews, Stanley B Pounds, et al.
Clinical Pharmacology and Therapeutics|June 18, 2016
Comparison of genome sequencing and clinical genotyping for pharmacogenesW Yang, G Wu, U Broeckel, et al.
Leukemia|April 10, 2012
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemiaC Liu, J D Kawedia, C Cheng, et al.
Clinical Pharmacology and Therapeutics|December 17, 2024
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic EthnicityMaud Maillard, Jenny Q Nguyen, Wenjian Yang, et al.
Journal of the American Medical Informatics Association : JAMIA|August 28, 2013
Development and use of active clinical decision support for preemptive pharmacogenomicsGillian C Bell, Kristine R Crews, Mark R Wilkinson, et al.
Pageof 18

Showing results (121-130 of 173) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2018
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline UpdateNaren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2018
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline UpdateSharon H Giordano, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumorsWayne L Furman, Fariba Navid, Najat C Daw, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 13, 2014
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogeneticsJames M Hoffman, Cyrine E Haidar, Mark R Wilkinson, et al.
Blood|May 16, 2014
6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group studySmita Bhatia, Wendy Landier, Lindsey Hageman, et al.
Pharmacogenomics|April 1, 2011
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypesJatinder K Lamba, Kristine R Crews, Stanley B Pounds, et al.
Clinical Pharmacology and Therapeutics|June 18, 2016
Comparison of genome sequencing and clinical genotyping for pharmacogenesW Yang, G Wu, U Broeckel, et al.
Leukemia|April 10, 2012
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemiaC Liu, J D Kawedia, C Cheng, et al.
Clinical Pharmacology and Therapeutics|December 17, 2024
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic EthnicityMaud Maillard, Jenny Q Nguyen, Wenjian Yang, et al.
Journal of the American Medical Informatics Association : JAMIA|August 28, 2013
Development and use of active clinical decision support for preemptive pharmacogenomicsGillian C Bell, Kristine R Crews, Mark R Wilkinson, et al.
Pageof 18